Certara Products - Simcyp Archives | Page 2 of 23

Press Coverage

The end of animal testing? Transitioning to models is promising — but no silver bullet

The FDA has stated that the pharma industry must transition to using in vitro assays,…

CertaraJuly 21, 2025

Webinar

Certara’s Simcyp Educational Webinar Series Part 3: Understanding the Supersaturated Dissolution in the Digestive Tract with Modeling & Simulation Approaches [in Japanese]

CertaraJuly 16, 2025

Press Coverage

How is the pharmaceutical industry addressing global health inequities?

Explore Karen Rowland Yeo's insights on using Model-Informed Drug Development to address global health equities…

CertaraJune 17, 2025

Blog

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

With the release of the draft ICH M15 guidance, MIDD is no longer optional -…

CertaraJune 11, 2025

On-Demand Webinar

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…

CertaraMay 23, 2025

On-Demand Webinar

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

Part 3 in November: Understanding the Supersaturated Dissolution in the Digestive Tract with Modeling &…

CertaraMay 12, 2025

Blog

Essentials of Model-informed Drug Development in Oncology

Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…

CertaraMay 2, 2025

On-Demand Webinar

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…

CertaraApril 21, 2025

Case Study

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

GRIN Therapeutics, Inc., an affiliate of Neurvati Neurosciences, focuses on the research and development of…

CertaraApril 16, 2025

Press Coverage

FDA to phase out animal testing with AI and lab-based models

FDA aims to replace animal testing in drug development with AI and lab-based models, enhancing…

CertaraApril 11, 2025

Certara Products – Simcyp

The end of animal testing? Transitioning to models is promising — but no silver bullet

Certara’s Simcyp Educational Webinar Series Part 3: Understanding the Supersaturated Dissolution in the Digestive Tract with Modeling & Simulation Approaches [in Japanese]

How is the pharmaceutical industry addressing global health inequities?

Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance

Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance

Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?

Essentials of Model-informed Drug Development in Oncology

Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions

Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy

FDA to phase out animal testing with AI and lab-based models

Newsletter sign up

Quick links

Solutions

Contact